Bronstein, Gewirtz & Grossman LLC Urges Mereo BioPharma Group plc Investors to Act: Class Action Filed Alleging Investor Harm

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc and certain officers for alleged violations of federal securities laws during the Class Period from June 5, 2023, to December 26, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Mereo securities during the specified Class Period [2]. - The Complaint alleges that Mereo provided positive statements to investors while concealing material adverse facts regarding the Phase 3 ORBIT and COSMIC programs, which did not meet their primary endpoints [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by April 6, 2026, although sharing in any recovery does not require serving as lead plaintiff [4]. - A copy of the Complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].